MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 21, 2025
VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned
NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025
Read more at globenewswire.comNASDAQ:MDWD (6/23/2025, 3:51:37 PM)
19.01
-0.08 (-0.42%)
Find more stocks in the Stock Screener
